Q2 2025 Performance Strong revenue growth from acquisitions, enterprise accounts, and innovative clinical solutions Q2 2025 15.2% Total revenue $2.76 billion 16.9% Adjusted operating income %2 11.5% Adjusted diluted EPS2 $2.62 per share 1 1,3 Company overview Quest is a leader in diagnostic testing insights and information services. Read our Q2 earnings press release on our Investor Relations site. " Through continued execution of our strategy, we delivered a strong second quarter, with revenues growing 15. ...

In its upcoming report, Labcorp Holdings (LH) is predicted by Wall Street analysts to post quarterly earnings of $4.14 per share, reflecting an increase of 5.1% compared to the same period last year. Revenues are forecasted to be $3.49 billion, representing a year-over-year increase of 8.3%.The consensus EPS estimate for the quarter has undergone a downward revision of 0.1% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their ini ...

Investors are always looking for stocks that are poised to beat at earnings season and Quest Diagnostics Incorporated (DGX) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Quest Diagnostics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible ...

Key Takeaways LH's Q2 revenues are estimated to be $3.49B, up 8.3% year over year, with EPS expected to rise 5.1% to $4.14. Diagnostics growth is driven by acquisitions, partnerships, and expanded specialty lab services. New Alzheimer's and oncology tests likely supported LH's top-line gains in the second quarter.Labcorp Holdings Inc. (LH) , or Labcorp, is slated to report second-quarter 2025 results on July 24, before the opening bell.The renowned laboratory service provider reported adjusted earnings of ...

CARLSBAD, Calif., July 17, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing solutions, announced today the appointment of Chas McKhann to its Board of Directors, effective July 17, 2025. Mr. McKhann is an accomplished leader with over 25 years of experience in the life sciences industry, including Board and C-suite positions leading turnaround and transformational growth at multiple medical technology companies. Most recently, Mr. McKhann served as Boar ...

The sale of a piece of a Cerba Healthcare bank loan signals lenders are seeking to trim their exposure to the French laboratories business before the start of debt talks https://t.co/pPRX9aKA2B ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? Dev ...

Core Viewpoint - Labcorp Holdings (LH) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of earnings estimate revisions, which are strongly correlated with near-term stock price movements [4][6]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [4]. Labcorp's Earnings Outlook - For the fiscal year ending December 2025, Labcorp is expected to earn $16.05 per share, with a 0.3% increase in the Zacks Consensus Estimate over the past three months [8]. - The upgrade reflects an improvement in Labcorp's underlying business, which is likely to drive the stock price higher as investors respond positively to this trend [5][10]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [7]. - Labcorp's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [9][10].

Core Insights - Quest Diagnostics (DGX) has experienced a significant share price increase of 27.3% over the past year, outperforming the industry and S&P 500 [1][8] - The company is currently rated Zacks Rank 2 (Buy) and is benefiting from investments in Advanced Diagnostics, which enhance patient care and drive growth [2] Company Overview - Headquartered in Secaucus, NJ, Quest Diagnostics provides a wide range of diagnostic information services and serves as a key provider of reference testing for about half of U.S. hospitals [3] - The company aims for annual revenue growth of 1-2% through targeted acquisitions [3] Growth Catalysts - The growth of Quest Diagnostics is primarily driven by its strength in Advanced Diagnostics, particularly in areas such as cardiometabolic, autoimmune, brain health, oncology, and women's health [4] - There is robust demand for Alzheimer's disease risk detection blood tests, and the company plans to introduce new biomarkers for better assessment of dementia [4] - The company has expanded its women's health offerings with a new self-collection option for HPV cervical cancer screening [4] - Quest Diagnostics anticipates revenue generation from its Haystack minimal-residual disease (MRD) test this year [4] Acquisitions and Partnerships - In 2024, the company completed eight acquisitions, including LifeLabs in Canada and Allina Health, to maximize productivity [5] - New health plan partnerships with Elevance Health and Sentara Health Plans are expected to drive volume and revenue gains [6] - Quest Diagnostics became the first independent national lab selected for the Optum Health preferred lab network, gaining access to over 85,000 physicians [6] Operational Efficiency - The company targets 3% annual cost savings and productivity improvements through its Invigorate cost-savings program [9] Financial Estimates - The Zacks Consensus Estimate for Quest Diagnostics' 2025 and 2026 earnings per share (EPS) is projected to increase by 8.6% and 8.2%, reaching $9.70 and $10.50 respectively [11] - Revenues for 2025 are expected to grow by 9.2% to $10.78 billion, followed by a 3.7% increase to $11.19 billion in 2026 [11]

Core Viewpoint - Quest Diagnostics (DGX) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with near-term stock price movements, particularly due to institutional investors' reliance on these estimates for valuation [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations for stocks, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Company Performance and Outlook - The upgrade for Quest Diagnostics signifies an improvement in its underlying business, which is expected to drive the stock price higher as investors respond positively to this trend [5][10]. - Analysts project that Quest Diagnostics will earn $9.70 per share for the fiscal year ending December 2025, with a slight increase of 0.1% in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system categorizes stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a "Strong Buy" or "Buy" rating, indicating superior potential for market-beating returns [9][10]. - The Zacks Rank 2 for Quest Diagnostics places it among the top 20% of stocks covered by Zacks, suggesting a favorable outlook for the stock in the near term [10].